Ratings Seikagaku Corporation

Equities

4548

JP3414000004

Market Closed - Japan Exchange Other stock markets 11:30:00 28/06/2024 am IST			5-day change	1st Jan Change
879 ^JPY	-0.90%		+1.85%	+15.51%

08/04	Ferring Pharmaceuticals Inc. Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603, in Lumbar Disc Herniation at ASIPP 2024	CI
2023	Seikagaku Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
The company appears to be poorly valued given its net asset value.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
With a 2024 P/E ratio at 18.43 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SEIKAGAKU CORPORATION	+15.51%	301M	-
ELI LILLY AND COMPANY	+55.32%	819B	C+
JOHNSON & JOHNSON	-6.75%	351B	C+
MERCK & CO., INC.	+13.56%	329B	B-
ABBVIE INC.	+10.68%	298B	C+
ASTRAZENECA PLC	+16.57%	242B	B+
ROCHE HOLDING AG	+2.04%	225B	A+
NOVARTIS AG	+13.31%	217B	B-
AMGEN INC.	+8.48%	168B	C+
PFIZER, INC.	-2.81%	158B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes